What causes dyspnea in patients with hypermobile Ehlers-Danlos Syndrome (hEDS)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Mechanisms of Dyspnea in Hypermobile Ehlers-Danlos Syndrome

Dyspnea in hEDS is primarily caused by respiratory muscle weakness, which is present in approximately 77% of patients, combined with structural airway abnormalities and autonomic dysfunction. 1, 2

Primary Respiratory Mechanisms

Inspiratory Muscle Weakness

  • Reduced inspiratory muscle strength (SNIP <80% predicted) occurs in 77% of hEDS patients and is the predominant cause of exertional dyspnea. 2
  • Inspiratory muscle weakness leads to blunted tidal volume expansion during exercise, which is the primary mechanism of dyspnea perception rather than indices of inspiratory effort. 3
  • The connective tissue abnormalities in hEDS—specifically softer, less stiff connective tissue with altered collagen fibril structure—likely compromise the structural integrity of respiratory muscles and their fascial attachments. 3, 4

Airway Structural Abnormalities

  • Upper and lower airway collapse occurs due to connective tissue laxity affecting the trachea and bronchi, contributing to dyspnea during exertion. 5, 6
  • Tracheobronchomalacia is a recognized structural manifestation that causes dynamic airway collapse during breathing. 7
  • Chest wall abnormalities including pectus deformities, scoliosis, and recurrent rib subluxations create mechanical constraints on ventilation. 7

Abnormal Lung Volumes

  • Despite normal baseline lung function, 24% of hEDS patients demonstrate higher-than-normal forced vital capacity (FVC) and 12% have elevated total lung capacity (TLC), suggesting altered chest wall compliance. 2
  • These volume abnormalities may reflect the generalized tissue laxity characteristic of hEDS affecting thoracic structures. 2

Secondary Contributing Factors

Autonomic Dysfunction (POTS)

  • Patients with hEDS and coexisting POTS experience more severe dyspnea due to orthostatic intolerance and altered cardiovascular responses to exercise. 3
  • The vascular laxity in hEDS may predispose to POTS through impaired venous return and peripheral pooling, exacerbating exercise intolerance. 3
  • Approximately 37.5% of hEDS patients report a diagnosis of POTS, which compounds respiratory symptoms through cardiovascular deconditioning. 3

Mast Cell Activation

  • MCAS occurs in a subset of hEDS patients and can cause bronchospasm and respiratory symptoms through histamine release and inflammatory mediator effects on airways. 3
  • Mast cells migrate into connective tissue including respiratory mucosa, where excessive degranulation can trigger asthma-like symptoms. 8
  • However, MCAS should only be suspected when multisystem symptoms are present, not for isolated dyspnea. 3

Breathing Pattern Disorders

  • Inducible laryngeal obstruction and exercise-induced hyperventilation may be misdiagnosed as asthma in hEDS patients. 7, 3
  • Dysfunctional breathing patterns with increased respiratory frequency and reduced tidal volume occur due to mechanical constraints. 3

Differential Considerations

Distinguishing from Other Causes

  • True asthma coexists in some hEDS patients and should be evaluated with standard spirometry and bronchoprovocation testing. 5, 6
  • Gastroesophageal reflux disease is common in hEDS (reported in over 60% of patients with GI symptoms) and can contribute to respiratory symptoms through aspiration or reflex bronchoconstriction. 3, 7
  • Sleep apnea has high prevalence in non-vascular EDS types and contributes to daytime dyspnea through sleep fragmentation and nocturnal hypoxemia. 5

Critical Pitfall

  • Do not assume dyspnea in hEDS is purely deconditioning or anxiety-related without objective assessment of respiratory muscle strength using SNIP measurements. 2 The high prevalence of measurable inspiratory muscle weakness (77%) means this is a treatable organic cause that should not be missed. 2

Clinical Assessment Approach

Measure sniff nasal inspiratory pressure (SNIP) in all hEDS patients with dyspnea, as this identifies the 77% with respiratory muscle weakness who will benefit from targeted inspiratory muscle training. 2

  • Perform standard spirometry to assess for obstructive or restrictive patterns, though baseline values are often normal. 2
  • Evaluate for chest wall deformities, scoliosis, and rib subluxations on physical examination. 7
  • Assess for POTS using postural vital signs if orthostatic symptoms accompany dyspnea. 3
  • Consider laryngoscopy if inspiratory stridor or voice changes suggest laryngeal involvement. 7

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Relationship Between hEDS, MCAS, and Obesity

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

[Respiratory manifestations of Ehlers-Danlos syndromes].

Revue des maladies respiratoires, 2023

Research

Respiratory manifestations in the Ehlers-Danlos syndromes.

American journal of medical genetics. Part C, Seminars in medical genetics, 2021

Guideline

Impact of Hypermobile Ehlers-Danlos Syndrome on Adipose Tissue

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.